Study Of Angiomax In Infants Under Six Months With Thrombosis
Completed
The Medicines Company
Phase 2
2002-08-01
The goals of this study are:
1. To assess the safety of bivalirudin in infants under six months with arterial or venous
thrombosis;
2. To determine the dose of bivalirudin required to achieve adequate anticoagulation as
measured by the activated clotting time (ACT) or activated partial thromboplastin time
(aPTT) in Infants Under Six Months with arterial or venous thrombosis;
3. To determine the outcome of patients on bivalirudin with respect to thrombus resolution
and bleeding complications compared to patients on unfractionated heparin (UH) or low
molecular weight heparin (LMWH).
Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE)
Completed
The Medicines Company
Phase 3
2003-10-01
The purpose of this study is to examine the safety and efficacy of Angiomax as an
anticoagulation in patients with heparin-induced thrombocytopenia (HIT)/heparin-induced
thrombocytopenia with thrombosis syndrome (HITTS) undergoing off-pump coronary artery bypass
(OPCAB) surgery.
Comparing Angiomax to Heparin With Protamine Reversal in Patients OPCAB
Completed
The Medicines Company
Phase 3
2003-08-01
The purpose of this study is to examine the safety and efficacy of Angiomax as an alternative
anticoagulant to heparin with protamine reversal in patients undergoing off-pump coronary
artery bypass graft surgery.
Angiomax in Patients With HIT/HITTS Type II Undergoing CPB
Completed
The Medicines Company
Phase 3
2004-04-01
The purpose of this study is to demonstrate that in patients with heparin-induced
thrombocytopenia (HIT)/heparin-induced thrombocytopenia and thrombosis syndrome (HITTS) Type
II undergoing cardiac surgery on cardiopulmonary bypass (CPB), Angiomax is a safe and
effective anticoagulant.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
